- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Biocardia Inc (BCDA)
Biocardia Inc stock price live, this page displays NASDAQ BCDA stock exchange data. View the BCDA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Biocardia Inc real time stock price chart below.
What Is the Biocardia Inc Stock Price Today?
The Biocardia Inc stock price today is 0.824.
What Is the Stock Symbol for Biocardia Inc?
The stock symbol for Biocardia Inc is "BCDA."
What Stock Exchange Does Biocardia Inc Trade On?
Biocardia Inc is listed and trades on the NASDAQ stock exchange.
Is Biocardia Inc a Good Stock to Buy?
Determining whether Biocardia Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BCDA quote. (ISIN: US09060U6064)
What Is the Biocardia Inc Stock Price Today?
The Biocardia Inc stock price today is 0.824.
What Is the Stock Symbol for Biocardia Inc?
The stock symbol for Biocardia Inc is "BCDA."
What Stock Exchange Does Biocardia Inc Trade On?
Biocardia Inc is listed and trades on the NASDAQ stock exchange.
Is Biocardia Inc a Good Stock to Buy?
Determining whether Biocardia Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BCDA quote. (ISIN: US09060U6064)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.790
0.825
52 wk Range
0.750
2.290
Earnings results expected in 9 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.7900.825
52 wk Range
0.7502.290
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BCDA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
15.500
Upside
+1,781.07%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Form 4 Biocardia Inc For: 10 July- Investing.com
Form 4 Biocardia Inc For: 29 July- Investing.com
- Form 4 Biocardia Inc For: 29 July
- Investing.com
Form 4 Biocardia Inc For: 15 July- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 15.500
(+1,781.07% Upside)
Biocardia Inc SWOT Analysis
Pivotal Trial Phase | BioCardia's CardiAMP cell therapy system enters critical Phase 3 trial, with potential to revolutionize heart failure treatment amid financial challenges |
Regulatory Milestones | FDA protocol amendment and CMS reimbursement approval boost CardiAMP HF II trial, expanding patient eligibility and mitigating study costs |
Market Dynamics | Explore BioCardia's position in the competitive cell therapy landscape, with promising early results setting high expectations for cardiovascular treatment |
Financial Outlook | Analysts project trial completion by 2025, with price targets ranging from $4 to $25, despite current negative EBITDA and cash burn concerns |
Biocardia Inc Earnings Call Summary for Q1/2026
- BioCardia reduced total expenses 17% YoY to $2.3M; net loss improved 14.8% to $2.3M despite limited $951K cash position and 53% stock decline.
- CardiAMP Heart Failure Trial demonstrated promising clinical progress; company advancing cell therapy program amid operational improvements.
- Plans Q2 2026 funding transactions to support Japan PMDA submission and CardiAMP Heart Failure II trial enrollment; 7-month submission timeline expected.
- Japan market represents $400M opportunity; regulatory approval timeline approximately 19 months, with analyst price targets ranging $6-$25.
- Operating cash burn increased slightly to $1.7M; CEO emphasizes financial discipline while advancing clinical milestones and regulatory approvals.
Last Updated: 05/16/2026, 05:12 AM
Read Full TranscriptEarnings
Latest Release
May 15, 2026
EPS / Forecast
-0.21 / --
Revenue / Forecast
-- / --
Compare BCDA to Peers and Sector
Metrics to compare | BCDA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBCDAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.2x | −1.3x | −0.4x | |
PEG Ratio | −0.02 | −0.04 | 0.00 | |
Price/Book | −8.8x | 1.4x | 2.6x | |
Price / LTM Sales | - | 60.7x | 3.0x | |
Upside (Analyst Target) | - | 333.1% | 56.0% | |
Fair Value Upside | Unlock | 12.2% | 9.1% | Unlock |
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company’s lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Biocardia (BCDA) Stock Price Today?
The Biocardia stock price today is 0.824 USD.
What Stock Exchange Does Biocardia Trade On?
Biocardia is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Biocardia?
The stock symbol for Biocardia is "BCDA."
What Is the Biocardia Market Cap?
As of today, Biocardia market cap is 9.380M USD.
What Is Biocardia's Earnings Per Share (TTM)?
The Biocardia EPS (TTM) is -0.947.
When Is the Next Biocardia Earnings Date?
Biocardia will release its next earnings report on Aug 12, 2026.
From a Technical Analysis Perspective, Is BCDA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Biocardia Stock Split?
Biocardia has split 6 times.
How Many Employees Does Biocardia Have?
Biocardia has 19 employees.
What is the current trading status of Biocardia (BCDA)?
As of Aug 03, 2026, Biocardia (BCDA) is trading at a price of 0.824 USD, with a previous close of 0.824 USD. The stock has fluctuated within a day range of 0.790 USD to 0.825 USD, while its 52-week range spans from 0.750 USD to 2.290 USD.
What Is Biocardia (BCDA) Price Target According to Analysts?
The average 12-month price target for Biocardia is 15.500 USD, with a high estimate of 25 USD and a low estimate of 6 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +1,781.07% Upside potential.
What Is the BCDA Premarket Price?
BCDA's last pre-market stock price is 0.800 USD. The pre-market share volume is 520.000, and the stock has decreased by 0.029, or 3.760%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.